Charles Schwab Investment Management Inc Altimmune, Inc. Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALT
# of Institutions
185Shares Held
44.4MCall Options Held
1.1MPut Options Held
647K-
State Street Corp Boston, MA8.65MShares$58.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.04MShares$27.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.13MShares$21.1 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.5 Million3.41% of portfolio
-
Morgan Stanley New York, NY2.21MShares$14.9 Million0.0% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $330M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...